Literature DB >> 2457654

Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy.

A A Ilyas1, H J Willison, M C Dalakas, J N Whitaker, R H Quarles.   

Abstract

IgM monoclonal antibodies from three patients with polyneuropathy associated with biclonal gammopathy reacted with monosialoganglioside GM1 on thin-layer chromatograms. An IgM paraprotein in one of the patients with a predominantly motor neuropathy also reacted strongly with the ganglioside GD1b and asialo-GM1. All three of these antigenic lipids have a Gal(beta 1-3)GalNAc moiety in common which would appear to be the antigenic determinant. However, this IgM also cross-reacted weakly with paragloboside which has an N-acetyllactosaminyl [Gal(beta 1-4)GlcNAc] terminal structure. The specificity of the other paraprotein in this patient is not known. The IgM paraproteins reacting with GM1 in both of the other patients exhibited different specificity because they did not react with GD1b and asialo-GM1, but reacted strongly with GM2 ganglioside. The data suggest that the epitope for both of these IgMs is in the GalNAc(beta 1-4)(NeuAc alpha 2-3)Gal(beta 1-4)Glc region of the gangliosides that is common to both GM2 and GM1. The second IgM paraproteins in both of these latter patients react with the myelin-associated glycoprotein (MAG) and two 3-sulfoglucuronyl glycolipids that share antigenic determinants with MAG.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457654     DOI: 10.1111/j.1471-4159.1988.tb01821.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.

Authors:  Abraham C J Stork; W-Ludo van der Pol; Hessel Franssen; Bart C Jacobs; Nicolette C Notermans
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

2.  Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins.

Authors:  H J Willison; G Paterson; J Veitch; G Inglis; S C Barnett
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

3.  Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier.

Authors:  F P Thomas; W Trojaborg; C Nagy; M Santoro; S A Sadiq; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Acute motor neuropathy with antibodies to GM1 ganglioside.

Authors:  N A Gregson; D Jones; P K Thomas; H J Willison
Journal:  J Neurol       Date:  1991-12       Impact factor: 4.849

5.  The anti-oligosaccharide antibodies present in sera from patients with motor neuron disease and neuropathy recognize the N-glycolylneuraminic acid containing gangliotetrahexosyl oligosaccharide.

Authors:  M Carpo; E Nobile-Orazio; V Chigorno; S Sonnino
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

6.  Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Authors:  Amjad A Ilyas; Zi-Wei Chen
Journal:  J Neuroimmunol       Date:  2007-06-07       Impact factor: 3.478

Review 7.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 8.  Ganglioside function in the development and repair of the nervous system. From basic science to clinical application.

Authors:  S D Skaper; A Leon; G Toffano
Journal:  Mol Neurobiol       Date:  1989       Impact factor: 5.590

9.  Ganglioside antibodies: a lack of diagnostic specificity and clinical utility?

Authors:  M Weller; A Stevens; N Sommer; J Dichgans; B Kappler; H Wiethölter
Journal:  J Neurol       Date:  1992-10       Impact factor: 4.849

10.  Immunological mechanisms of demyelination.

Authors:  R A Hughes
Journal:  J R Soc Med       Date:  1992-01       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.